RxDoctor Payments Data

Norma Garcia

Family · Richland, WANPI 1881842839

Payments from drug & device makers

$1,107in general payments, 2019–2025

Across 20 payments — averaging $55.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$297
  • AbbVie$244
  • W. L. Gore & Associates, Inc.$217
  • Ardelyx, Inc.$109
  • Janssen Scientific Affairs, LLC$86
  • Pfizer$76
  • plus $78 from 3 others

What the payments were for

  • Food & beverage$1,107100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,107 in reported general payments places this provider in the 80th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$99,708
Medicare patients
580
Services billed
883

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide110$65,762
CreonLipase/Protease/Amylase27$50,632
Mesalamine19$17,846
MovantikNaloxegol Oxalate34$17,466
TrulancePlecanatide28$17,040
Famotidine862$16,393
Pantoprazole Sodium655$9,119
Lubiprostone69$6,326
Lansoprazole195$4,761
Ursodiol25$4,363
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates67$4,314
DexilantDexlansoprazole12$4,072
SutabSod Sulf/Pot Chloride/Mag Sulf23$3,766
Dicyclomine Hcl150$3,152
Sucralfate81$2,804

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$244$116,394137 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$16$17,04028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,706 family providers in Washington.

Other family in Richland

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →